Literature DB >> 27745933

Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia.

C Borghi1, R Urso2, A F Cicero2.   

Abstract

AIM: The aim of this study is to discuss the reliable scientific evidence of an interactive link between hypertension and hypercholesterolemia considering the metabolic pathways and the pathogenetic mechanisms connecting the two risk factors. DATA SYNTHESIS: Hypertension and hypercholesterolemia are highly prevalent in the general population and their coexistence in the same subjects additively increases the risk of cardiovascular disease. Probably, hypercholesterolemia is also a risk factor for the development of hypertension. On the other side, it is also possible that lipid-lowering treatment could improve blood pressure control. Although the mechanisms of interaction between these two risk factors have not been completely elucidated thus far, there is rapidly growing evidence that the involvement of the renin-angiotensin system (RAS) can be considered as the common link between hypertension and hypercholesterolemia. In particular, hypercholesterolemia seems to promote the upregulation of type 1 angiotensin II (AT1) receptor genes because of an increase in the stability of mRNA followed by structural overexpression of vascular AT1 receptors for angiotensin II. The treatment of both risk factors greatly improves individual risk profile, especially when statins and RAS blockers are used together.
CONCLUSIONS: Hypertension and hypercholesterolemia are highly coprevalent and strongly related from a pathophysiological point of view. The RAS could be the main mediator of this link.
Copyright © 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Hypercholesterolemia; Hypertension; RAS; Statins

Mesh:

Substances:

Year:  2016        PMID: 27745933     DOI: 10.1016/j.numecd.2016.07.013

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  12 in total

Review 1.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

2.  Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008.

Authors:  Chi Ren; Weiming Liu; Xue Yin; Bingyu Zhang; Peirong Lu
Journal:  J Ophthalmol       Date:  2020-06-24       Impact factor: 1.909

3.  Predictors of the transition from metabolically healthy obesity to unhealthy obesity.

Authors:  Luisa Gilardini; Antonella Zambon; Davide Soranna; Marina Croci; Cecilia Invitti
Journal:  Eat Weight Disord       Date:  2018-10-29       Impact factor: 4.652

4.  Antihypertensive Treatment Patterns and Blood Pressure Control in Older Adults: Results from the Berlin Aging Study II.

Authors:  Maximilian König; Maik Gollasch; Adrian Rosada; Ilja Demuth; Dominik Spira; Elisabeth Steinhagen-Thiessen
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

5.  Angiotensin II induces cholesterol accumulation and injury in podocytes.

Authors:  Yingjie Yang; Qian Yang; Jian Yang; Yiqiong Ma; Guohua Ding
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

6.  Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

7.  High Remnant Cholesterol Level Potentiates the Development of Hypertension.

Authors:  Ming-Ming Chen; Xuewei Huang; Chengsheng Xu; Xiao-Hui Song; Ye-Mao Liu; Dongai Yao; Huiming Lu; Gang Wang; Gui-Lan Zhang; Ze Chen; Tao Sun; Chengzhang Yang; Fang Lei; Juan-Juan Qin; Yan-Xiao Ji; Peng Zhang; Xiao-Jing Zhang; Lihua Zhu; Jingjing Cai; Feng Wan; Zhi-Gang She; Hongliang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

8.  Repurposing existing drugs for COVID-19: an endocrinology perspective.

Authors:  Flavio A Cadegiani
Journal:  BMC Endocr Disord       Date:  2020-09-29       Impact factor: 2.763

9.  Impacts of renin-angiotensin system inhibitors on two-year clinical outcomes in diabetic and dyslipidemic acute myocardial infarction patients after a successful percutaneous coronary intervention using newer-generation drug-eluting stents.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

10.  Associations between remnant lipoprotein cholesterol and central systolic blood pressure in a Chinese community-based population: a cross-sectional study.

Authors:  Jing Zhou; Yan Zhang; Kaiyin Li; Fangfang Fan; Bo Zheng; Jia Jia; Bo Liu; Jiahui Liu; Chuyun Chen; Yong Huo
Journal:  Lipids Health Dis       Date:  2021-06-26       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.